The Maldives Food and Drug Authority (MFDA) has issued a public alert concerning quality issues in specific batches of the drug Immuglo, manufactured by the Indian pharmaceutical company Ichor Biologicals Ltd.

This announcement follows reports from the National Medicine Regulatory Authority of Sri Lanka and the World Health Organization (WHO), which identified quality concerns in certain batches of the medication.

In its statement, the MFDA clarified that Ichor Biologicals is not authorized to import or sell medicines in the Maldives.

Additionally, no batches of Immuglo have been legally imported under Maldives’ pharmaceutical regulations. 

However, given that many Maldivians seek medical treatment in India and Sri Lanka, the MFDA has urged the public to remain vigilant.

The drug in question, Normal Immunoglobulin for intravenous use 5% BP (Immuglo), has been flagged for the following batch numbers: IG24002AD, IG24001AD, IG24004AD, and IG24003AD.

This alert is part of a broader MFDA effort to address the influx of substandard medicines, with a significant portion originating from India.

The agency has recently increased its inspections to ensure the quality and safety of imported pharmaceuticals.